Catalyst: Firdapse Cliff Deferred, But Capital Allocation Still An Issue (Upgrade)
Source: SeekingAlpha
2025-12-03 17:37:42 ET
Introduction
Today, I am revisiting Catalyst Pharmaceuticals, Inc. ( CPRX ). I last wrote about this company in September 2024. Things were looking bleak at that time. Catalyst’s flagship drug, FIRDAPSE, appeared to be on the verge of losing market exclusivity amid a legal battle with Teva Pharmaceutical ( TEVA )....
Read the full article on Seeking Alpha
For further details see:
Catalyst: Firdapse Cliff Deferred, But Capital Allocation Still An Issue (Upgrade)
Teva Pharmaceutical Industries Ltd
NASDAQ: TEVJF
TEVJF Trading
43530.77% G/L:
$28.36 Last:
100 Volume:
$28.36 Open:
TEVJF Latest News
June 06, 2025 09:44:00 am
Teva 2024 Healthy Future Report: Health System Strengthening and Capacity Building
TEVJF Stock Data
$39,634,050,594
1,138,314,769
N/A
264
N/A
Pharmaceuticals
Healthcare
IL
Tel Aviv
